Revance Therapeutics Inc News - RVNC

Empower your portfolio: Real-time discussions and actionable trading ideas.

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced new hire grants totaling an aggregate of 104,800 inducement restricted stock units...

Revance to Participate in Upcoming Investor Conferences

Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced that the company will be participating in the following investor conferences. William...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update

- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million...

Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia

DAXXIFY® for the treatment of cervical dystonia is the first and only peptide-formulated, long-lasting neurotoxin that offers the potential to...

Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024

Conference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ: RVNC), today announced that the company...

Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting

– Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing...

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 4 - Statement of changes in beneficial ownership of securities

randychub 6 hours ago

Probably one of the most important quarters for the company to see if they righted the ship.

I’d say give it another 1/2 year but hoping like everyone else hoping the 100 million + quarterly growth increase is headed our way.

👍️ 4

biotech_researcher 6 hours ago

The proportionally larger number of Instagram posts by patients and clinics on the use and benefits of Daxxify tells the story where those Botox sales went.. we will know soon.

Probably one of the most important quarters for the company to see if they righted the ship.

👍️ 3

alertmeipp 7 hours ago

Either customers have pulled back significantly or Botox is finally losing its market share

or both I guess.

👍️ 2

DewDiligence 8 hours ago

Other than the first half of 2020 (onset of the COVID pandemic) and one or two quarters during the 2008-2009 financial crisis, it had never happened until now.

👍️ 5 🤨 1

vinmantoo 8 hours ago

The $100M reduction in Botox sales guidance is for cosmetic indications, specifically.

I sure hope a competitor product is taking market share from ABBV. You can guess which competitor is one I hope is taking market share. The stock ticker begins with an R and ends with a C. 😆

👍️ 1 😂 1

randychub 10 hours ago

Do happen to know the last time they had a quarter that was nil?

“YoY change in Botox volume — excluding the restocking effect — was essentially nil.”

👍️ 2

mrwilson31 21 hours ago

Appreciate it

👍️0

DewDiligence 22 hours ago

The $100M reduction in Botox sales guidance is for cosmetic indications, specifically.

For related info, please see #msg-174811564.

👍️ 2

mrwilson31 23 hours ago

Is that for cosmetic or therapeutic?
I thought AbbVie had growth in that area.

👍️0

Emannow 1 day ago

Scott Reents (AbbVie)
"Given slower-than-expected near-term market growth, particularly in the U.S. and China, as a result, our total sales guidance for Botox and Juvederm will each be lower by roughly $100 million".

Botox lower by $100 million AND Juvederm lower by $100 million....

Interesting as US sales for Evolus, Galderma and Revance are all growing at double digits... but the same US market is not growing in Allergan's Analytics....Humm...maybe Allergan needs to hire a new Analytics Group.

And Botox unit sales are still below their 2 year level.

👍️ 2

go seek 1 day ago

*Any idea as to what caused the sharp decline at the close today? Large sell order(s)?

👍️0

DewDiligence 1 day ago

ABBV lowered 2024 Botox guidance by $100M compared to the guidance given three months ago. (Source: today's 2Q24 CC.)

👍️ 5

go seek 1 day ago

Yes, this logic holds if the shorts still consider The stock a sell and expect a continued slide in the price / share. I do not know what the shorts think, but one would think they would be concerned when the stock moved up 50% in 3 weeks. Best to you vin.

👍️0

vinmantoo 1 day ago

Hi vin, I am surprised… i thought the total short position would be less, given the recent run up.

go seek, my rationale is that if shorts are convinced RVNC is a failure then the higher price would make it a better bet to short. This may be backwards but I have never shorted a stock so maybe I don't understand it.

FYI, the economic data was pretty good today and seems to be lifting most stocks.

👍️0

Emannow 1 day ago

AbbVie domestic Botox sales 2022 Q2 $449 million, AbbVie domestic Botox sales 2023 Q2 $420 million, AbbVie Domestic Botox sales 2024 Q2 $450 million with a 4% price increase...If you remove the 4% price increase Botox sales for 2024 Q2 = $432 million...Botox is still $18 million behind 2022 Q2 number at $449 million....Botox is definitely losing TOXIN MARKET SHARE....the AbbVie Executive Team is not truthful!

👍️ 2

go seek 2 days ago

With yesterday’s poor US economic data, we may see an interest rate cut sooner rather than later.

👍️0

go seek 2 days ago

Hi vin, I am surprised… i thought the total short position would be less, given the recent run up. It is difficult to assess given there is a time lag in the short report.

👍️ 1

vinmantoo 2 days ago

Shorts are now 16.3 million…all time high!

The RVNC stock price bounced back from the $2.30 low a few weeks ago to almost double that price so I am not surprised shorts are back in force.

👍️ 2

go seek 2 days ago

The shorts better cover or they will burn🔥

👍️ 1

Emannow 2 days ago

Shorts are now 16.3 million…all time high! Is Foley is a total idiot??? Did he destroy Revance?

👍️0

go seek 3 days ago

Next earnings report on 5 August…
It appears daily volume is picking up.

👍️0

Tal10 3 days ago

I wouldn't doubt if the rally extends right into the earnings release. Technical traders are jumping in with the cup and handle trade, and any hint of positive news between now and earnings could trigger a major squeeze.

Nice to see that the RVNC roller coaster has resumed its upward swing.

👍️ 1 🫡 1

apm_com 4 days ago

Perhaps a little insight from a competitor on Q2 activity and 2nd half potential:

Evolus to Report Second Quarter Financial Results on July 31, 2024
Business Wire
NEWPORT BEACH, Calif.-(BUSINESS WIRE) --Evolus, Inc. (EOLS.NaE), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its second quarter 2024 financial results on Wednesday, July 31, 2024, after the U.S. financial markets close.
Evolus (EOLS.NaE) management will host a conference call and live webcast to discuss these results at 4:30 p.m. ET that same day. A question-and-answer session will follow management's remarks.
To participate in the conference call, dial (877) 407-6184 (U.S.)

👍️ 1

Tomdontworry 6 days ago

If all holds true, we should find out China’s first approval by 8/13.

👍️0

rock mountain 6 days ago

Fosun made two press releases in April and July 2023 in regard to the submission of Daxxify, for cosmetic treatment and the treatment of cervical dystonia, stating that China's NMPA accepted both applications for review. Other source state that median approval for compounds was 15,4 months (2017 -2021). Generally imported drugs take longer but the trend for approval times is going down. My guess is thus that we will see approval this Q3 or Q4 - and yes I agree that we will not see a significant impact of royalty payments from Fosun this FY. Buckle-up for 2025 as RVNC will make a significant impact in relaxing those necks in the PR of China.

👍️ 2 😂 2

go seek 1 week ago

Also beyond approval milestone payment(s)
I doubt Revance will receive royalty revenue from (China) Daxi sales this year.

👍️0

DewDiligence 1 week ago

Fosun Pharma will issue a press release when China's NMPA approves Daxxify for marketing.

👍️ 2

Jab44 1 week ago

It comes from the NMPA. I’m not sure exactly whether they share the approval on line .

👍️0

Jlinvest01 1 week ago

If approved, does the company have to report it? They could keep it for themselves and mix it into Q2 report. Which wouldn't be a positive.
Any ways to track china approvals directly?

👍️0

Jab44 1 week ago

That is what I’m waiting for. It would be a boost to get the registration before announcing second quarter results. Of course when Abbvie announces the analytics begin with extrapolating the Botox loss of market share and who is capturing it.

👍️ 1

rock mountain 1 week ago

Any news on the registration in the PR of China? That should be a big boost.

👍️0

Jlinvest01 1 week ago

Question is, what would the board do, in case of an unsolicited offer at this stage? Management would have to present it to them. If board would decide to launch request to other parties, they would have to pr it, and things could move up a lot real fast.

👍️ 1

Kydg 1 week ago

How about Abbvie sales?

👍️ 2

Emannow 1 week ago

Just like J&J who bought Mentor Breast implants and is now the #1 breast implant company in the WORLD (destroyed Allergan breast market share) RVNC will be bought by a large Pharma company, and Daxi will become the #1 toxin in the world!

It is short sighted for AbbVie to short RVNC. The Allergan executive management team is leaving one after another in the last 12 months. The management team sees the writing on the wall and knows Botox which is 20 plus yrs old and Juvederm will continue to lose market share! Allergan is not filling many positions when executives leave! Allergan is cutting costs to try and match decreasing revenues!

👍️ 1

Kydg 1 week ago

RVNC is the only one with unique and better products. The others are all botox biosimilars but their market cap is higher than RVNC. That makes 0 sense.

Keeping RVNC share prices extremely low is their only chance to survive. If SP goes above 10$,and RVNC raise 200m,in 2 years RVNC will kill all competitors.

👍️ 3

Emannow 1 week ago

Totally agree! AbbVie is highly shorting RVNC to keep the SP low in an effort to bankrupt RVNC so RVNC can not raise funds by selling shares! Abbive knows Daxi is replacing Botox in many accounts!

Just did an analysis with a large practice (annual Allergan purchases of $700,000 plus) which was 100% Botox and Juvederm for the last 15 yrs and over the last 9 months switched to Daxi and RHA. Their gross toxin revenue is down 6% but their toxin net profit is up 9%. They are making more profits off each patient. Additionally, variable and fixed costs are also down 8% and the injectors now have free patient space to fill over the next 12 months as they convert new patients and the USA toxin market grows 12 to 14%. They Love, love RHA and completely eliminated Juvederm. Patients LOVE Daxi and do not want Botox..this practice has completely eliminated the need for the Allergan rep in the office. Allergan knows this will happen!!!

👍️ 4 💯 1

go seek 1 week ago

RVNC’s share price is kept low by competitors, I believe.
I doubt it.

👍️0

Jlinvest01 1 week ago

Shorts won't scare until we break 150dma. Below = no brrainer reload for them / Higher = they run for hills.
Might not happen in Q2, but therapeutics sales have a lot of upwards potential. Company took conservative approach because of aestethics set backs. But i strongly believe that dynamics will be different on therapeutic side.

👍️ 1

Kydg 1 week ago

RVNC’s share price is kept low by competitors, I believe.

👍️ 1

vinmantoo 1 week ago

Doesn't matter.

I was just joking. I didn't mean to suggest I was upset or worried. Someone whose name won't get mentioned made uninformed, reckless and inaccurate comments about Taiwan a day or two ago and the Chip/AI sector got crushed and drove the market down. Looks like that trend is continuing somewhat today.

Need good data to break the 150/200 dma. Without it, these lines will remain a glass ceiling. All hinges on execution by management. The product took shares to 40+, execution took it to 2$.

We are on the same page.

👍️0

Jlinvest01 1 week ago

Doesn't matter. Need good data to break the 150/200 dma. Without it, these lines will remain a glass ceiling. All hinges on execution by management. The product took shares to 40+, execution took it to 2$.

👍️0

go seek 1 week ago

and easy come again… more easy come than easy go! 😂

👍️0

vinmantoo 1 week ago

Uh oh, easy come, easy go.

👍️0

DewDiligence 1 week ago

Re: AEON I am puzzled by the substantial increase in AEON's stock price… You have to put it in perspective. AEON is still down sharply from its closing price on 5/2/24, the day before they reported the failed phase-2 trial in migraine prevention (#msg-174352699). In my opinion, there is little to anticipate from CD, given [ABP-450’s] comparable duration to Botox. AEON is pursing CD because they think it’s the most direct route to FDA approval of ABP-450 as a Botox biosimilar. Note that AEON has to stick to therapeutic indications because EOLS owns the commercial rights to the drug in aesthetic indications. (AEON’s ABP-450 and EOLS’ Jeuveau are the exact same drug.)

As noted in #msg-174726891, AEON is nearly insolvent and hence it’s hard to see how they complete a phase-3 trial to obtain FDA approval using the 351(k) pathway. It’s possible that the recent bounce in the share price stems from a leak that such funding is forthcoming from somewhere.

👍️ 3

ASPRV 1 week ago

Is there an alternative method to forecast Daxxify revenue aside from monitoring Instagram or TikTok trends?

I'm frustrated with the volatility following earnings reports.

I recently acquired additional shares at $2.80, but this hasn't significantly lowered my average price.

Additionally, I am puzzled by the substantial increase in AEON's stock price. In my opinion, there is little to anticipate from CD, given its comparable duration to Botox. Furthermore, they were unsuccessful in the migraine market.

👍️0

TechandBio 1 week ago

Revance my modest options from 2 weeks ago are up 123% also adding shares of ICCM curing early and later stage breast cancer patients with 97% complete response rate after 5 years. reminds me of PLSE when i started buying shares at 1.30s a few years ago,

$RVNC

👍️0

Jlinvest01 1 week ago

Q2 numbers only need to show that trajectory (either sales or volume, but prefereably volume) to break even by eoy '25, is intact. This, and only this will scare them shorts. From 2$ to 4$ is nothing, merely a correction of an overreaction.

👍️ 1

biotech_researcher 1 week ago

It was about time for a re-test..

👍️ 1

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Revance Therapeutics Inc (RVNC)

Empower your portfolio: Real-time discussions and actionable trading ideas.

RVNC News

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revance to Participate in Upcoming Investor Conferences

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update

Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia

Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024

Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

RVNC Discussion

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Revance Therapeutics Inc (RVNC) News

Revance Therapeutics Inc (RVNC)

Empower your portfolio: Real-time discussions and actionable trading ideas.

RVNC News

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Revance to Participate in Upcoming Investor Conferences

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update

Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia

Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024

Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting

Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

RVNC Discussion

Your Recent History

Company

Business

Popular

Get The App